Drug Profile
Research programme: monoclonal antibody therapeutics - ImmuneXcite Technology
Alternative Names: mAbXcite antibodies; mAbXcite-cetuximab; mAbXcite-trastuzumabLatest Information Update: 24 Jul 2023
Price :
$50
*
At a glance
- Originator ImmuneXcite
- Class Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Breast cancer; Colorectal cancer
Most Recent Events
- 24 Jul 2023 Discontinued - Preclinical for Breast cancer in USA (unspecified route)
- 24 Jul 2023 Discontinued - Preclinical for Colorectal cancer in USA (unspecified route)
- 28 May 2019 No recent reports of development identified for preclinical development in Breast-cancer in USA